Generic Name: luspatercept
Brand Name: Reblozyl
Manufacturer: Celgene Inc. / Bristol-Myers Squibb Canada Co.
Therapeutic Area: beta-thalassemia associated anemia
Indications: For the treatment of adult patients with red blood cell (RBC) transfusion-dependent anemia associated with beta(β)-thalassemia
Manufacturer Requested Reimbursement Criteria1: For the treatment of adult patients with β-thalassemia associated anemia who require red blood cell (RBC) transfusions.
Submission Type: Initial
Project Status: Pending
Call for patient/clinician input open: October 29, 2020
Call for patient/clinician input closed: December 17, 2020
Anticipated Date: November 26, 2020
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.